Xiaoying Shen

Dec 2, 2024 | dialnet.unirioja.es | Wei Sun |Xiaoying Shen |Xinyi Wang |Xiaoyan Zhang

Ayuda Buscar en la ayuda Buscar en la ayuda Correlation of NAT10 expression with clinical data and survival profiles in esophageal squamous cell carcinoma patients, and its impact on cell proliferation and apoptosis Wei Sun [1] ; Xiaoying Shen [2] ; Xinyi Wang [1] ; Xiaoyan Zhang [2] ; Yongling Ji [1] ; Jin Wang [1] [1] Zhejiang Cancer Hospital, Hangzhou, PR China [2] Shanghai OUTDO Biotech Co. Ltd., Shanghai, China Localización: Histology and histopathology: cellular and molecular biology,...

Nov 26, 2024 | nature.com | Xiaoying Shen |Ryan Tuck |Robert Edwards |Yunfei Wang |Kshitij Wagh |Kevin Saunders | +3 more

AbstractThe details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in neonatal macaque undergoing Simian-HIV infection. Simian-HIV infection of 11 pairs of therapy-naive dams and infant rhesus macaques for 24 months results in heterologous HIV-1 neutralizing antibodies in 64% of young macaques compared to 18% of adult macaques.

Nov 4, 2023 | nature.com | Ivy Phung |Kristen A. Rodrigues |Ester Marina-Zárate |Bapi Pahar |Wen-Hsin Lee |Pyone P. Aye | +13 more

AbstractAdjuvants and antigen delivery kinetics can profoundly influence B cell responses and should be critically considered in rational vaccine design, particularly for difficult neutralizing antibody targets such as human immunodeficiency virus (HIV). Antigen kinetics can change depending on the delivery method.

Aug 31, 2023 | nature.com | Spyros Chalkias |Joanne E. Tomassini |Xing Chen |Xiaoying Shen |Darin Edwards |Stephen Walsh

AbstractThis ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Two groups of adults who previously received mRNA-1273 as primary vaccination series and booster doses were enrolled in a sequential, nonrandomized manner and received single-second boosters of mRNA-1273 (n = 376) or bivalent mRNA-1273.222 (n = 511).